secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179834
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Q2 net loss $21.0M, cash $147.6M; advances ACR-368 and ACR-2316 trials
------------------------------------------------------------------------------

- Net loss of $21.0M for Q2 2025, up from $18.8M in Q2 2024; R&D spend $16.2M.
- Cash, equivalents and investments of $147.6M as of June 30, 2025; expected runway into Q2 2027.
- Initiated Phase 2b third arm for ACR-368 with ultra low-dose gemcitabine in biomarker-unselected endometrial cancer.
- ACR-2316 Phase 1 dose escalation shows initial clinical activity, including confirmed partial response in endometrial cancer.
- Anticipated H2 2025 milestones: update on registrational ACR-368 trial and initial Phase 1 data for ACR-2316.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312525179834/0001193125-25-179834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312525179834/acrv-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer